
Currently out of the existing stock ratings of Robin Garner, 11 are a BUY (100%).
Analyst Robin Garner, has had 40% of price targets met with an average potential upside of 82.02%, reached in 146 days on average. Previously, Robin Garner worked at CRAIG HALLUM.
Robin Garner has documented 24 price targets and ratings displayed on 5 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on AVDL, Avadel Pharmaceuticals PLC at 12-Jan-2024.
Analyst best performing recommendations are on PCSA (PROCESSA PHARMACEUTICALS).
The best stock recommendation documented was for AVDL (AVADEL PHARMACEUTICALS PLC) on 5/27/2022. The price target of $15.5 was fulfilled within 348 days with a profit of $13 (520%), with a performance score of 14.94.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 19-Oct-2021
$20.42
$500
2 years 7 months 21 days ago
(01-Apr-2024)
0/2 (0%)
$-1.18 (-5.46%)
Hold Since 06-Jan-2023
$1
$14
3 years 10 months 16 days ago
(06-Jan-2023)
1/4 (25%)
$-3.05 (-75.31%)
713
Hold Since 12-Aug-2022
4 years 11 days ago
(11-Nov-2022)
0/2 (0%)
$53.4 (50.09%)
Buy Since 01-Mar-2021
$60
$90
4 years 3 months 10 days ago
(12-Aug-2022)
0/3 (0%)
$49.4 (466.04%)
Hold Since 01-Mar-2021
$70
$170
4 years 10 months 19 days ago
(03-Jan-2022)
0/2 (0%)
$17.8 (34.10%)